News | Breast Density | June 28, 2017

New Study Highlights Breakthrough Therapy to Reduce Mammographic Breast Density

Therapy combining testosterone and aromatase inhibitor found to reduce fibroglandular breast density by nearly 20 percent

New Study Highlights Breakthrough Therapy to Reduce Mammographic Breast Density

June 26, 2017 — Stephen N. Birrell, M.D., Ph.D., presented breakthrough findings into the reduction of mammographic breast density at the 8th International Breast Densitometry and Cancer Risk Assessment Conference in San Francisco. The conference, co-chaired by University of California San Francisco and Karolinska Institutet, included presentations and posters by researchers from institutions across the world, including the Mayo Clinic and Queen Mary University of London.

Birrell, chief medical officer of HAVAH Therapeutics, undertook a study to examine the effect of the company's T+Ai (testosterone plus aromatase inhibitor) therapy that intends to mimic the effects of tamoxifen by reducing mammographic breast density in pre-menopausal women without perturbations in hypothalamic-pituitary function. One hundred and fifty women undergoing mammographic screening and having high mammographic breast density as determined by a percent volumetric breast density (%VBD) measurement of equal to or greater than 15.5 VBD as measured by Volpara, were randomly chosen for inclusion in the study. A VBD of 15.5 percent is equivalent to a BI-RADS D classification.

The participants were allocated in a non-randomized fashion to either (a) follow-up mammography at 1 year for mammographic breast density calculation or (b) treatment with a subcutaneous pellet of testosterone (60-100 mg) and anastrozole (1-3mg) (dependent on BMI) every 4 months plus a follow-up mammogram for mammographic breast density calculation at 1 year. There were no significant differences in the base-line characteristics of each cohort. Hormone levels were evaluated every 4 months and follicular stimulating (FSH) and luteinizing hormones (LH) were compared from baseline to the same stage of each woman's menstrual cycle 3 months later. Serum anastrozole levels were measured at 1 and 4 months after treatment was commenced.

Seventy-four women were included in the cohort study (2 lost in pre-screening). None were lost to follow-up during the study period. There was a small (2 percent) reduction in mean %VBD in the control group compared to the treatment cohort (19.5 percent). There was no significant change in either FSH or LH. There were no serious adverse events and no androgenicity events resulting in cessation of treatment.

In conclusion, testosterone combined with anastrozole is an effective method of reducing high mammographic breast density in pre-menopausal women. This is achieved by manipulating the amplified hormone catalytic enzymatic system of high mammographic breast density tissue to effect an alteration in the breast tissue estrogen to testosterone ratio; thus inducing a state of breast tissue involution commensurate with that occurring with tamoxifen chemoprevention. This was achieved with excellent tolerance and no adverse effect on hypothalamic-pituitary function.

Birrell's cohort study results were supported by a poster presentation regarding a secondary study on the effect of T+Ai in reducing breast tissue stiffness and breast pain in a cohort of 10 women. A clear signal was observed with all women experiencing a reduction in tissue stiffness and pain of 53 percent and 67 percent, respectively.

For more information: www.havahtherapeutics.com

Related Content

Smoking is strongly linked to lower use of cancer screening services by women, and more advanced disease once cancer is diagnosed, reveals research published in the online journal BMJ Open.

Getty Images

News | Lung Imaging | August 14, 2020
August 14, 2020 — Smoking is strongly linked to lower use of...
Results of Journal of the American College of Surgeons study should reassure breast cancer patients who experienced surgical postponements due to COVID-19 pandemic

Association between Time to Operation and Pathological Stage in DCIS & ER+ Breast Cancer. Courtesy of American College of Surgeons

News | Women's Health | August 07, 2020
August 7, 2020 — A new br...

An oncologist practices social distancing while talking to a cancer patient. Image courtesy of University of Michigan Rogel Cancer Center

News | Coronavirus (COVID-19) | August 07, 2020
August 7, 2020 — When COVID-19 struck, health ca
As part of an international collaboration, researchers from Aarhus University and University of Leicester have succeeded in developing a dynamic 3-D CT scanning method that shows what happens inside the body during simulated heart massage

A look inside cardiopulmonary resuscitation: A 4-D computed tomography model of simulated closed chest compression. A proof of concept. Courtesy of Kasper Hansen/Jonathan Bjerg Moeller/Aarhus University

News | Cardiac Imaging | August 07, 2020
August 7, 2020 — Rapid first aid during...
Collaboration will include data sharing, R&D and an upgrade of RadNet’s fleet of mammography systems to Hologic’s state-of-the-art imaging technology
News | Breast Imaging | August 06, 2020
August 6, 2020 — RadNet, Inc., a national leader in providing hig
Ghost imaging approach could enable detailed movies of the heart with low-dose X-rays

Researchers developed a high-resolution X-ray imaging technique based on ghost imaging that can capture the motion of rapidly moving objects. They used it to create a movie of a blade rotating at 100,000 frames per second. Image courtesy of Sharon Shwartz, Bar-Ilan University

News | X-Ray | August 06, 2020
August 6, 2020 — Researche...
Hologic, Inc. launched the Back to Screening campaign encouraging women to schedule their annual mammograms now that healthcare facilities across the nation are re-opening their doors following closures due to the COVID-19 pandemic.

Nine-time GRAMMY Award winner and breast cancer survivor Sheryl Crow has served as the spokesperson for Hologic’s Genius 3D Mammography exam for nearly five years.

News | Breast Imaging | August 03, 2020
August 3, 2020 — Hologic, Inc. launched the Back to Screening campaign encouraging women to schedule their ann
It covers every major modality, including breast imaging/mammography, fixed and portable C-arms (cath, IR/angio, hybrid, OR), CT, MRI, nuclear medicine, radiographic fluoroscopy, ultrasound and X-ray
News | Radiology Imaging | July 29, 2020
July 29, 2020 — IMV Medical Information, part of Scien...
Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

News | Prostate Cancer | July 28, 2020
July 28, 2020 — A study published in